The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.
The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.
This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.
Participants will be asked to return for 6 visits across 12 months to evaluate their health.
Across the UK the trial aims to recruit 10,260 volunteers.
If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.